Transient Ischemic Attacks
8
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Translational Immunodiagnostics in Stroke (TrImS)
Atrial Fibrillation as a Cause of Stroke and Intracranial Hemorrhage Study (The FibStroke Study)
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack
Improved Delivery of Cardiovascular Care Through Outreach Facilitation